Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANTX | An2 Therapeutics | $5.75 | $2.90 | 101.75% | 49.6M | $78M | $1.00$6.91 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $2.04 | $0.92 | 81.70% | 146.5M | - | $0.88$55.77 |
| CAMP | Camp4 Therapeutics | $7.59 | $3.39 | 80.59% | 3.2M | $218M | $1.31$7.75 |
| DTCK | Davis Commodities | $2.42 | $0.99 | 69.23% | 26.6M | $39M | $1.32$137.80 |
| RLMD | Relmada Therapeutics | $6.58 | $2.13 | 47.87% | 35.7M | $326M | $0.24$6.64 |
| XENE | Xenon Pharmaceuticals | $61.37 | $19.43 | 46.33% | 530.1K | $3.5B | $26.74$62.74 |
| TURB | Turbo Energy | $5.45 | $1.67 | 44.18% | 20.6M | $42M | $0.57$20.45 |
| HIMS | Hims & Hers Health | $22.18 | $6.44 | 40.91% | 5.4M | $3.6B | $13.74$70.43 |
| EPSM | Epsium Enterprise | $2.45 | $0.71 | 40.80% | 2M | $23M | $1.04$155.00 |
| ATRA | Atara Biotherapeutics | $7.14 | $1.97 | 38.10% | 61K | $37M | $3.92$19.15 |
| NERV | Minerva Neurosciences | $7.91 | $1.90 | 31.53% | 352K | $260M | $1.15$12.46 |
| PLYX | Polaryx Therapeutics | $3.48 | $0.74 | 27.01% | 602.7K | $130M | $2.20$48.91 |
| RNAC | Cartesian Therapeutics | $8.69 | $1.84 | 26.86% | 2.5M | $178M | $5.98$18.80 |
| CCCC | C4 Therapeutics | $3.76 | $0.72 | 23.68% | 202.3K | $297M | $1.09$3.82 |
| DDD | 3D Systems | $2.40 | $0.44 | 22.45% | 200.2K | $252M | $1.32$3.80 |
| QURE | uniQure | $17.40 | $3.13 | 21.93% | 474.1K | $879M | $7.76$71.50 |
| LSTA | Lisata Therapeutics | $5.03 | $0.85 | 20.34% | 386.8K | $37M | $1.81$5.06 |
| DNTH | Dianthus Therapeutics | $76.84 | $11.64 | 17.85% | 110.8K | $2.8B | $13.37$84.78 |
| KC | Kingsoft Cloud | $14.10 | $2.11 | 17.60% | 109.1K | $3.5B | $10.29$19.57 |
| PURR | Hyperliquid Strategies | $5.09 | $0.76 | 17.55% | 6.4M | $537M | $3.01$5.78 |
| CRVO | CervoMed | $4.81 | $0.70 | 17.03% | 12.3K | $38M | $1.92$16.94 |
| CRBP | Corbus Pharmaceuticals | $9.36 | $1.35 | 16.85% | 339.3K | $141M | $4.64$20.56 |
| SLDB | Solid Biosciences | $7.85 | $1.10 | 16.22% | 80.3K | $526M | $2.41$8.15 |
| BEG | Themes ETF Trust - Leverage Shares 2x Long Be Daily ETF | $30.38 | $4.24 | 16.21% | 36K | - | $10.89$50.61 |
| RGNX | Regenxbio | $10.03 | $1.38 | 15.95% | 1.3M | $438M | $5.04$16.19 |
| ATLN | Atlantic International | $3.32 | $0.43 | 14.88% | 1.6K | $181M | $1.16$6.50 |
| VRTL | GraniteShares ETF Trust - GraniteShares 2x Long Vrt Daily ETF | $113.00 | $14.11 | 14.26% | 180.7K | - | $7.57$119.89 |
| AGCC | Agencia Comercial Spirits | $20.68 | $2.57 | 14.19% | 11.6K | $623M | $3.66$24.98 |
| EEIQ | EpicQuest Education Group International | $2.62 | $0.32 | 13.91% | 106.8K | $3.4M | $2.21$27.84 |
Related Articles
Featured Article
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
Geoffrey Seiler|Mar 9, 2026
Hims & Hers stock traded more than 40% higher after the deal was announced.
Hims & Hers Stock Pops 40%: Everything You Need to Know
Travis Hoium|Mar 9, 2026
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
